Bionomics Inc.

Merck Sharp + Dohme Corp.

Fabrice Garrido

Dharam Paul

Christophe Morice

Rajinder Singh

Hamish Toop

Patrick Bazzini

Jean-Marie Contreras

Florence Chery

Ian M Bell

Andrew John Harvey

Anthony J Roecker

Brian T Campbell

Brendan M Crowley

Kenneth J Leavitt

Belinda C Huff

Laurent Schaeffer

Christophe Joseph

Aurelie Witzel

Erin Smith

Celine Michaut-Simon

James Fells

The present disclosure relates to compounds of formula I that are useful as modulators of α7 nAChR, compositions comprising such compounds, and the use of such compounds for preventing, treating, or ameliorating disease, particularly disorders of the central nervous system such as cognitive impairments in Alzheimer's disease, Parkinson's disease, and schizophrenia, as well as for L-DOPA induced-dyskinesia and inflammation

Spiropiperidine allosteric modulators of nicotinic acetylcholine receptors

Activators of Kv3.1 and/or Kv3.2 channels which are therapeutically useful in the treatment of cognitive dysfunction and the negative symptoms which are associated with central nervous system disorders such as schizophrenia, Alzheimer's disease, Tourette's syndrome, autism, dementia, epilepsy and other disorders where gamma oscillations are dysfunctional are provided. The activators include substituted N-heteroaryl compounds.

Substituted-N-heteroaryl compounds and uses thereof

The present application relates generally to compounds useful for the treatment and/or enhancement of cognitive dysfunction and negative symptoms associated with CNS disorders where the circuitry involving fast spiking PV+ interneurons and the production of cortical gamma oscillations is disrupted. The subject disclosure enables the manufacture of medicaments as well as compositions containing same for use in methods of therapy and prophylaxis of cognitive dysfunction and negative symptoms.

Substituted-pyridinyl compounds and uses thereof

Growing community of inventors

Illkirch, France

Fabrice Garrido